Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
| 3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
| 2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
| 1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
| 9/14/2022 | $40.00 | Outperform | SVB Leerink |
| 9/9/2022 | $15.00 | Underweight | Morgan Stanley |
| 3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors, with potential for expanded therapeutic index - Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025 - Focused prioritization and disciplined capital deployment
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe
Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data in chronic hepatitis B from MARCH Phase 2 study to be shared in oral presentation Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating c
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)
DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)
S-8 - Vir Biotechnology, Inc. (0001706431) (Filer)